Laplace Interventional, a US-based medical device company focusing on transcatheter valve technology, recently announced the ...
The Society for Cardiovascular Angiography & Interventions (SCAI) has published a first-of-its-kind educational resource for interventional cardiologists and imaging specialists performing ...
In this randomized controlled trial, a transcatheter tricuspid-valve replacement provided a mortality benefit compared to ...
Payment will be provided when TTVR is delivered for an FDA-approved indication in the context of a CMS-approved study.
Background Cardiac surgery carries a heightened risk of bradyarrhythmias, but current permanent pacemaker (PPM) implantation ...
CMS has approved Medicare and Medicaid coverage for transcatheter tricuspid valve replacement procedures for the treatment of ...
Ben McCullough, 76, received an EVOQUE heart valve last fall. On Wednesday, he got to thank the makers face-to-face.
To the Editor: In the TRISCEND II trial, Hahn and colleagues (Jan. 9 issue) 1 concluded that transcatheter tricuspid-valve replacement plus medical therapy was superior to medical therapy alone.
Medical Device Network on MSN12d
Laplace raises funding to complete study of tricuspid valve technologyLaplace has raised $22m in a Series C financing round to support the completion of EFS of transcatheter tricuspid valve technology.
The chordae tendineae (CT), often referred to as the “heart strings,” are thin, tendinous structures that connect the heart ...
Opens in a new tab or window Based on the finalized national coverage determination (NCD) for transcatheter tricuspid valve replacement, Medicare will cover the procedure when used for an FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback